LeMaitre Vascular (LMAT) Getting Somewhat Favorable Press Coverage, Report Shows

News stories about LeMaitre Vascular (NASDAQ:LMAT) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LeMaitre Vascular earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.1895953557238 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Several equities analysts recently commented on the stock. BidaskClub lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Benchmark Co. raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price target (up previously from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Tuesday, August 1st. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price target on shares of LeMaitre Vascular in a research report on Monday, October 9th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) traded down $0.55 during mid-day trading on Friday, reaching $34.56. 201,445 shares of the company traded hands, compared to its average volume of 181,483. LeMaitre Vascular has a 1 year low of $19.82 and a 1 year high of $39.88. The firm has a market capitalization of $667.90, a price-to-earnings ratio of 44.52, a price-to-earnings-growth ratio of 2.72 and a beta of 0.55.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a net margin of 20.31% and a return on equity of 19.79%. The firm had revenue of $24.80 million during the quarter, compared to analyst estimates of $25.49 million. During the same quarter in the prior year, the business posted $0.17 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 6.9% compared to the same quarter last year. sell-side analysts forecast that LeMaitre Vascular will post 0.84 EPS for the current year.

LeMaitre Vascular announced that its board has initiated a stock repurchase program on Thursday, July 27th that allows the company to repurchase $7.50 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 1.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 7th. Stockholders of record on Wednesday, November 22nd will be given a $0.055 dividend. This represents a $0.22 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Tuesday, November 21st. LeMaitre Vascular’s payout ratio is currently 28.21%.

In other news, insider David B. Roberts sold 26,683 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $36.67, for a total value of $978,465.61. Following the completion of the sale, the insider now owns 48,108 shares of the company’s stock, valued at $1,764,120.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman George W. Lemaitre sold 40,000 shares of the stock in a transaction on Friday, August 25th. The stock was sold at an average price of $33.89, for a total transaction of $1,355,600.00. Following the completion of the sale, the chairman now directly owns 3,390,508 shares of the company’s stock, valued at approximately $114,904,316.12. The disclosure for this sale can be found here. Insiders sold 150,806 shares of company stock valued at $5,346,329 in the last three months. Company insiders own 23.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “LeMaitre Vascular (LMAT) Getting Somewhat Favorable Press Coverage, Report Shows” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/18/lemaitre-vascular-lmat-getting-somewhat-favorable-press-coverage-report-shows.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply